Differentiated Protein Products Built on a World-Leading Strain Optimisation Platform
Phenotypeca applies its proprietary QTL strain optimisation technology to develop a growing portfolio of biological products with commercial impact, including:
- Scalable, cost-effective biosimilars
- Novel therapeutic candidates with high commercial potential
- Advanced peptides for skincare and consumer health
Each product leverages our platform’s unique ability to evolve entire genomes for optimal function — delivering performance, consistency, and IP protection.
Biosimilars
Strain-Optimised Biosimilars for Scalable Manufacture
We develop proprietary production strains that achieve reference standard bioequivalence while outperforming on key manufacturing metrics: yield, quality, reproducibility, and cost.
- Semaglutide – Semi-recombinant manufacturing strain available
- Recombinant Albumin – High-yield, cost-effective production
- Sargramostim (GM-CSF) – Optimised strain for acute radiation syndrome
Download Semaglutide Summary PDF
Download Albumin Summary PDF
Download Sargramostim Summary PDF
Biological Therapeutics
High-Value Breakthrough Therapeutics with Low Technical Risk
Our pipeline targets areas of unmet clinical need using:
- Full-genome strain optimisation
- Evolutionary functional genomics
- Strategic partnerships with complementary technology platforms
We pursue high-impact opportunities where our platform reduces technical risk and accelerates development.
- VHH antibody therapy for plaque psoriasis
- VHH antibody therapy for atopic dermatitis
- HPV vaccine candidate
- Neoantigen cancer vaccine platform
- Recombinant albumin for chronic liver disease
- Biological therapeutic for peripheral artery disease
Peptides for Skincare & Consumer Products
Recombinant Peptides to Unlock Consumer Innovation
Our QTL platform enables scalable production of peptides that are difficult or impossible to synthesise by conventional methods.
We support brands and manufacturers by providing:
- Access to large or complex peptides
- Proprietary peptides with novel mechanisms of action
- Cost-effective production of existing peptides
Contact us to discuss partnership or supply opportunities.